An Open-label, Multicenter, Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of Multiple Combination Therapies With FWD1802 in Subjects With ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
Latest Information Update: 09 Jun 2025
At a glance
- Drugs Abemaciclib (Primary) ; Everolimus (Primary) ; FWD 1802 (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary)
- Indications HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Forward Pharma
Most Recent Events
- 09 Jun 2025 New trial record